Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

Wed, 15 Jul 2026 08:00:00 -0400

SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will participate in a panel discussion at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference on Wednesday, July 22, 2026, at 3:00 pm ET.

Webcast Link Instructions
A webcast of the panel can be accessed under "Events" in the investor relations section of the Belite Bio website at:

Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

Wed, 15 Jul 2026 08:00:00 -0400

Webcast Link Instructions
A webcast of the panel can be accessed under "Events" in the investor relations section of the Belite Bio website at:

Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium

Mon, 06 Jul 2026 08:00:00 -0400

SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will participate in a fireside chat at the Piper Sandler Virtual Ophthalmology Investor Symposium on Thursday, July 9, 2026, at 12:30 pm ET.

Webcast Link Instructions
A webcast of the presentation can be accessed under "Events" in the investor relations section of the Belite Bio website at:

Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium

Mon, 06 Jul 2026 08:00:00 -0400

Webcast Link Instructions
A webcast of the presentation can be accessed under "Events" in the investor relations section of the Belite Bio website at:

Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

Mon, 06 Jul 2026 07:00:00 -0400

SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio^®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that Belite data will be presented at the 63rd Annual Symposium of the International Society for Clinical Electrophysiology of Vision (ISCEV) being held on July 6-11, 2026, in Sydney, Australia, and the American Society of Retina Specialists (ASRS) 2026 Annual Meeting being held on July 15-18, 2026, in Montréal, Canada.

Presentation Details
Session: Session

Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

Mon, 06 Jul 2026 07:00:00 -0400

Presentation Details
Session: Session

Form 4 BELITE BIO, INC For: Jun 18 Filed by: Scholl Hendrik Peter

Mon, 22 Jun 2026 06:06:00 -0400

si-local-file:///var/storage/secattach/20260622/26669413.html

Form 4 BELITE BIO, INC For: Jun 18 Filed by: Scholl Hendrik Peter

Mon, 22 Jun 2026 06:06:00 -0400

si-local-file:///var/storage/secattach/20260622/26669413.html

Form 144 BELITE BIO, INC Filed by: Scholl Hendrik Peter

Thu, 18 Jun 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260618/26666481.html

Form 144 BELITE BIO, INC Filed by: Scholl Hendrik Peter

Thu, 18 Jun 2026 16:27:00 -0400

si-local-file:///var/storage/secattach/20260618/26666481.html

Form 4 BELITE BIO, INC For: Jun 16 Filed by: Scholl Hendrik Peter

Wed, 17 Jun 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260617/26656448.html

Form 4 BELITE BIO, INC For: Jun 16 Filed by: Scholl Hendrik Peter

Wed, 17 Jun 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260617/26656448.html

Form 144 BELITE BIO, INC Filed by: Scholl Hendrik Peter

Tue, 16 Jun 2026 19:11:00 -0400

si-local-file:///var/storage/secattach/20260616/26655659.html

Form 144 BELITE BIO, INC Filed by: Scholl Hendrik Peter

Tue, 16 Jun 2026 19:11:00 -0400

si-local-file:///var/storage/secattach/20260616/26655659.html

H.C. Wainwright Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)

Tue, 16 Jun 2026 06:44:25 -0400

H.C. Wainwright analyst Yi Chen reiterated a Buy rating and $200.00 price target on Belite Bio, Inc, ADR (NASDAQ: BLTE).

The analyst commented: "Last Friday, Belite Bio announced the completion of its rolling submission of a New Drug Application (NDA) to the U.S. FDA for tinlarebant as a once-daily oral therapy for the treatment of Stargardt disease type 1 (STGD1) caused by mutations in the ABCA4 gene. As a reminder, the rolling NDA was initiated in April 2026 and was submitted under Breakthrough Therapy designation. Management noted that the completed application will undergo the 60-day review period, and if accepted by

Form 6-K BELITE BIO, INC For: Jun 12

Mon, 15 Jun 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260615/26643681.html

Form 6-K BELITE BIO, INC For: Jun 12

Mon, 15 Jun 2026 06:07:00 -0400

si-local-file:///var/storage/secattach/20260615/26643681.html

Belite Bio completes FDA drug application for rare eye disease treatment

Mon, 15 Jun 2026 03:02:57 -0400

Belite Bio Inc (NASDAQ: BLTE) completed its rolling submission of a New Drug Application to the U.S. Food and Drug Administration for tinlarebant, an oral therapy for Stargardt disease type 1, according to a company statement.

The submission, initiated in April 2026, was filed under Breakthrough Therapy Designation. Stargardt disease type 1 is a rare inherited retinal disease caused by mutations in the ABCA4 gene that leads to progressive vision loss. The condition affects an estimated 53,000 people in the U.S., with no currently approved treatments available.

The completed application will undergo a 60-day FDA review period. If accepted, the agency will

Belite Bio completes FDA drug application for rare eye disease treatment

Mon, 15 Jun 2026 03:02:57 -0400

The completed application will undergo a 60-day FDA review period. If accepted, the agency will

Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1

Fri, 12 Jun 2026 21:30:00 -0400

SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio^®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced the completion of its rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant. Tinlarebant is an investigational, once-daily oral therapy for the treatment of Stargardt disease type 1 (STGD1), a rare, inherited retinal disease caused by mutations in the ABCA4 gene that leads to progressive

Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1

Fri, 12 Jun 2026 21:30:00 -0400

Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Tue, 02 Jun 2026 08:00:00 -0400

SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio^®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 4:00 pm ET.

Webcast Link Instructions
Webcasts of the presentations can be accessed under "Events" in the investor relations section of the Belite Bio website at: https://investors.belitebio.com/presentations-events/events.

Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Tue, 02 Jun 2026 08:00:00 -0400

Belite Bio, Inc, ADR (BLTE) PT Lowered to $215 at Mizuho

Tue, 26 May 2026 05:50:22 -0400

Mizuho analyst Graig Suvannavejh lowered the price target on Belite Bio, Inc, ADR (NASDAQ: BLTE) to $215.00 (from $223.00) while maintaining a Outperform rating.

The analyst comments "BLTE reported 1Q26 results last week, with the key takeaway that all major milestones for tinlarebant remain on track. Most significantly, in our view, BLTE reaffirmed that the rolling NDA submission for tinlarebant in Stargardt disease/STGD1 (which was initiated in April) should be completed this quarter, and with key commercial leadership positions now filled, we believe that BLTE is well-positioned to execute on a product launch next year. Bigger picture, while the stock has

Belite Bio, Inc, ADR (BLTE) PT Lowered to $215 at Mizuho

Tue, 26 May 2026 05:50:22 -0400

Mizuho analyst Graig Suvannavejh lowered the price target on Belite Bio, Inc, ADR (NASDAQ: BLTE) to $215.00 (from $223.00) while maintaining a Outperform rating.

StreetInsider.com News Articles

Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium

Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium

Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences

Form 4 BELITE BIO, INC For: Jun 18 Filed by: Scholl Hendrik Peter

Form 4 BELITE BIO, INC For: Jun 18 Filed by: Scholl Hendrik Peter

Form 144 BELITE BIO, INC Filed by: Scholl Hendrik Peter

Form 144 BELITE BIO, INC Filed by: Scholl Hendrik Peter

Form 4 BELITE BIO, INC For: Jun 16 Filed by: Scholl Hendrik Peter

Form 4 BELITE BIO, INC For: Jun 16 Filed by: Scholl Hendrik Peter

Form 144 BELITE BIO, INC Filed by: Scholl Hendrik Peter

Form 144 BELITE BIO, INC Filed by: Scholl Hendrik Peter

H.C. Wainwright Reiterates Buy Rating on Belite Bio, Inc, ADR (BLTE)

Form 6-K BELITE BIO, INC For: Jun 12

Form 6-K BELITE BIO, INC For: Jun 12

Belite Bio completes FDA drug application for rare eye disease treatment

Belite Bio completes FDA drug application for rare eye disease treatment

Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1

Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1

Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

Belite Bio, Inc, ADR (BLTE) PT Lowered to $215 at Mizuho

Belite Bio, Inc, ADR (BLTE) PT Lowered to $215 at Mizuho